论文部分内容阅读
目的探讨拉米夫定联合乙肝免疫球蛋白防治肝移植术后乙肝复发的临床治疗效果。方法肝移植手术患者60例,将所有患者按照肝移植术后乙肝复发的防治方法分为对照组和观察组,对照组患者采用拉米夫定口服;观察组患者在对照组的预防基础上加用乙肝免疫球蛋白静脉滴注或肌内注射。两组患者出院后,进行1~2年的随访,比较两组患者的乙肝复发情况。结果通过随访,发现对照组乙肝复发率30.0%显著高于对照组6.7%,差异有统计学意义(P<0.05);观察组患者的生存率也明显高于对照组,差异有统计学意义(P<0.05)。结论对肝移植手术患者采用拉米夫定联合乙肝免疫球蛋白法,可有效抑制其乙肝复发情况,且比较安全,提高患者的临床治疗效果以及生存率,因此在临床上具有较高的应用价值。
Objective To investigate the clinical efficacy of lamivudine combined with hepatitis B immunoglobulin in the prevention and treatment of hepatitis B recurrence after liver transplantation. Methods Sixty patients underwent liver transplantation. All patients were divided into control group and observation group according to the prevention and treatment of recurrent hepatitis B after liver transplantation. Patients in control group were treated with lamivudine orally. In observation group, With hepatitis B immunoglobulin intravenous infusion or intramuscular injection. Two groups of patients discharged after 1 to 2 years of follow-up, compared two groups of patients with hepatitis B recurrence. Results The follow-up showed that the recurrence rate of hepatitis B in the control group was significantly higher than that in the control group (30.0% vs 6.7%, P <0.05), and the survival rate in the observation group was significantly higher than that in the control group (the difference was statistically significant P <0.05). Conclusion Lamivudine combined with hepatitis B immunoglobulin method in patients undergoing liver transplantation can effectively inhibit the recurrence of hepatitis B and is safe and improves the clinical effect and survival rate of patients, so it has a high clinical value .